Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.23.2
Commitments and Contingencies (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 40 Months Ended 64 Months Ended
Jul. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
milestone
therapy
Mar. 31, 2020
USD ($)
milestone
Jun. 30, 2023
USD ($)
Dec. 31, 2018
unit
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Feb. 03, 2020
USD ($)
Operating Leased Assets [Line Items]                        
Payment received $ 2,000,000                      
Period after public launch to terminate agreement 3 years                      
Percentage of net present value of royalty payments 75.00%                      
Aevi                        
Operating Leased Assets [Line Items]                        
Milestone payment       $ 0                
Aevi                        
Operating Leased Assets [Line Items]                        
Number of milestones | milestone     2                  
Contingent consideration     $ 6,500,000                  
Ichorion                        
Operating Leased Assets [Line Items]                        
Number of milestones | milestone   3                    
Contingent consideration   $ 15,000,000.0                    
Milestone payment       0                
Milestone One | Aevi                        
Operating Leased Assets [Line Items]                        
Contingent consideration                       $ 2,000,000
Milestone One | Ichorion                        
Operating Leased Assets [Line Items]                        
Milestone payment           $ 6,000,000            
Milestone Two | Aevi                        
Operating Leased Assets [Line Items]                        
Contingent consideration                       $ 4,500,000
Milestone Two | Ichorion | Forecast                        
Operating Leased Assets [Line Items]                        
Milestone payment             $ 5,000,000          
Milestone Three | Ichorion                        
Operating Leased Assets [Line Items]                        
Milestone payment       0                
Milestone Three | Ichorion | Forecast                        
Operating Leased Assets [Line Items]                        
Milestone payment             $ 4,000,000          
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement                        
Operating Leased Assets [Line Items]                        
Upfront license fee                     $ 10,000,000  
Percent of payments received from sublicensing                     30.00%  
Research and development expense       0                
Cumulative expense recognized to date       0                
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone One                        
Operating Leased Assets [Line Items]                        
Maximum aggregate milestone payment                     $ 112,500,000  
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone Two                        
Operating Leased Assets [Line Items]                        
Maximum aggregate milestone payment                     $ 75,000,000  
Astellas Pharma, Inc. (Astellas) | AVTX-006 Astellas License Agreement                        
Operating Leased Assets [Line Items]                        
Upfront license fee       500,000                
Maximum aggregate milestone payment       5,500,000                
Research and development expense       0                
Cumulative expense recognized to date       500,000                
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement                        
Operating Leased Assets [Line Items]                        
Upfront license fee               $ 400,000        
Research and development expense       0                
Cumulative expense recognized to date       0                
Patent costs               500,000        
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone One                        
Operating Leased Assets [Line Items]                        
Maximum aggregate milestone payment               24,200,000        
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone Two                        
Operating Leased Assets [Line Items]                        
Maximum aggregate milestone payment               $ 50,000,000        
TRIS Pharma | Karbinal Agreement                        
Operating Leased Assets [Line Items]                        
Minimum quantity required | unit         70,000              
Make whole payment per unit (in dollars per share) | $ / shares         $ 30              
AVTX-301 Out-License | Alto                        
Operating Leased Assets [Line Items]                        
Maximum proceeds from milestones                   $ 18,600,000    
Revenue recognized from milestones to date       0                
AVTX-406 License Assignment | ES                        
Operating Leased Assets [Line Items]                        
Revenue recognized from milestones to date       $ 0                
AVTX-406 License Assignment | ES | Milestone One                        
Operating Leased Assets [Line Items]                        
Maximum proceeds from milestones                 $ 6,000,000      
AVTX-406 License Assignment | ES | Milestone Two                        
Operating Leased Assets [Line Items]                        
Maximum proceeds from milestones                 $ 20,000,000      
AVTX-801, AVTX-802, And AVTX-803 | Ichorion                        
Operating Leased Assets [Line Items]                        
Number of preclinical therapies | therapy   3                    
AVTX-913 | Ichorion                        
Operating Leased Assets [Line Items]                        
Number of preclinical therapies | therapy   1